Clinical Trials Logo

Filter by:
NCT ID: NCT03353831 Active, not recruiting - Clinical trials for Recurrent Ovarian Carcinoma

Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer

Start date: September 11, 2018
Phase: Phase 3
Study type: Interventional

This is a phase III, randomized, partially blinded, multicenter trial to evaluate the efficacy and safety of atezolizumab plus bevacizumab and chemotherapy compared to placebo plus bevacizumab and chemotherapy in patients with recurrent ovarian-, fallopian tube, or primary peritoneal cancer with 1st or 2nd relapse within 6 months after platinum based chemotherapy or 3rd relapse.

NCT ID: NCT03345823 Active, not recruiting - Crohn's Disease Clinical Trials

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433

U-ENDURE
Start date: March 21, 2018
Phase: Phase 3
Study type: Interventional

A multicenter study to evaluate the efficacy and safety of maintenance and long-term treatment administration of upadacitinib, an orally administered Janus kinase 1 inhibitor, in adult participants with Crohn's Disease.

NCT ID: NCT03342144 Active, not recruiting - Clinical trials for Chronic Lymphocytic Leukemia (CLL)

Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting

Start date: December 4, 2017
Phase:
Study type: Observational

An observational study to assess the effectiveness, health economic-relevant costs and participant reported outcomes in participants with Chronic lymphocytic leukemia (CLL) receiving venetoclax as a monotherapy or in combination with rituximab or obinutuzumab as prescribed at the discretion of the physician and in accordance with local clinical practice and label.

NCT ID: NCT03336658 Active, not recruiting - CRC Clinical Trials

Intratumoral Budding (ITB) in Preoperative Biopsies of Colon and Rectal Cancer

ITB
Start date: October 1, 2015
Phase:
Study type: Observational

All the preoperative biopsies of patients suffering colorectal cancer (CRC) will be immunohistochemically stained with a pancytokeratin marker to detect Tumor buds. then, the intratumoral buds (ITB) in the densest Region of Tumor buds, namely the "hot spot" will be counted. Subsequently, the probability of N stage (lymphnodes), M stage (metastases) and disease free survival (DFS) will be calculated based on an existing logistic Regression model already developed by our previous retrospective work. Additionally, a Standardisation of ITB using a well- established Software will develop an algorithm which will help to eliminate inter- observer variability of Tumor budding Counts.

NCT ID: NCT03319797 Active, not recruiting - Clinical trials for Cartilage Defects of the Knee

NOVOCART® Inject Plus for Cartilage Defects of the Knee

Start date: October 10, 2017
Phase: Phase 3
Study type: Interventional

Prospective, Multicenter, Single-arm Phase III Clinical Trial to Evaluate the Efficacy and Safety of NOVOCART® Inject plus in the Treatment of Cartilage Defects of the Knee. The primary objective of this trial is to demonstrate efficacy of NOVOCART® Inject plus for the treatment of cartilage defects of the knee based on the Knee injury and Osteoarthritis Outcome Score (KOOS) responder rate 24 month after transplantation.

NCT ID: NCT03312465 Active, not recruiting - Clinical trials for Arthritis, Rheumatoid

Anatomical Shoulder Domelock System Study

Start date: September 28, 2017
Phase:
Study type: Observational

The objectives of this study are to confirm safety and performance of the Anatomical Shoulder Domelock System when used in hemi or total shoulder arthroplasty by analysis of standard scoring systems, radiographs and adverse event records.

NCT ID: NCT03297593 Active, not recruiting - Clinical trials for Renal Cell Carcinoma

Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma

Start date: December 13, 2017
Phase: Phase 2
Study type: Interventional

Immunotherapy with checkpoint inhibitors that target PD-1 and CTLA-4 have shown activity in mRCC. However, the optimal schedule of the combination therapy has yet to be defined. The objective of the trial is to determine the efficacy of combination immunotherapy of nivolumab and ipilimumab in patients with metastatic renal cell carcinoma. The expansion phase shall address the role of ipilimumab in case of clinically insignificant progression.

NCT ID: NCT03288415 Active, not recruiting - Clinical trials for Splenic Marginal Zone Lymphoma

SMZL Molecular Prognostic Index

Start date: January 2017
Phase:
Study type: Observational

The study aims at developing and validating an integrated clinico-molecular model for an accurate survival prognostication in newly diagnosed SMZL.

NCT ID: NCT03287024 Active, not recruiting - Clinical trials for Pulmonary Artery Stenosis

BeGrow Study to Treat Pulmonary Artery (PA) Stenosis in Newborns and Infants

Start date: March 1, 2018
Phase: N/A
Study type: Interventional

Objective of the study is to assess safety and performance of the BeGrow Stent System for newborns and infants in pulmonary artery stenosis.

NCT ID: NCT03274687 Active, not recruiting - Clinical trials for Prostate Adenocarcinoma

Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer

Start date: July 28, 2017
Phase: Phase 3
Study type: Interventional

This randomized phase III trial studies how well hypofractionated radiation therapy works compared to conventional radiation therapy after surgery in treating patients with prostate cancer. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Conventional radiation therapy uses high energy x-rays, gamma rays, neutrons, protons, or other sources to kill tumor cells and shrink tumors. It is not yet known whether giving hypofractionated radiation therapy or conventional radiation therapy after surgery may work better in treating patients with prostate cancer.